Benzinga

Benzinga

Benzinga

mercredi, septembre 02

Crinetics Pharmaceuticals Inc

CRNXNASDAQ
Trade with Public
Trade with Public
$84.95
À la clôture: Sep 1, 5:00 PM EST
$84.97
0.020.02%
Après les heures: Aug 31, 7:26 PM EST
Fusions et acquisitions: Crinetics Pharmaceuticals (CRNX) was acquired by Vertex Pharmaceuticals (VRTX) on Tuesday, September 1, 2026 for $10B paid in cash
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerOptionsRapport sur les stocks

Crinetics Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Crinetics Pharmaceuticals (CRNX).

Price Target Range — 13 Quarters

Analyst Consensus — 19 Analysts

3S.Buy
9Buy
7Hold
Consensus RatingBuy# Analysts19Avg. Consensus PT$82Upside to Avg. PT-3.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jul 28, 2026UBSAshwani VermaDowngradeBuy→Neutral$55→$85
Jul 8, 2026TD CowenTyler Van BurenDowngradeBuy→Hold—
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
UBS Downgrades Crinetics Pharmaceuticals to Neutral, Raises Price Target to $85

UBS analyst Ashwani Verma downgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) from Buy to Neutral and raises the price target from $55 to $85.
Benzinga Newsdesk

PRO
TD Cowen Downgrades Crinetics Pharmaceuticals to Hold

TD Cowen analyst Tyler Van Buren downgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) from Buy to Hold.
Benzinga Newsdesk

PRO
Evercore ISI Group Downgrades Crinetics Pharmaceuticals to In-Line, Lowers Price Target to $85

Evercore ISI Group analyst Gavin Clark-Gartner downgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) from Outperform to In-Line and lowers the price target from $88 to $85.
Benzinga Newsdesk

PRO
Oppenheimer Downgrades Crinetics Pharmaceuticals to Perform

Oppenheimer analyst Leland Gershell downgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) from Outperform to Perform.
Benzinga Newsdesk

Vertex Sees Over $5 Billion Peak Sales Potential From Crinetics Assets

Vertex to acquire Crinetics for $10 billion, adding approved acromegaly drug Palsonify and late-stage CAH candidate atumelnant to its rare disease portfolio.
Vandana Singh

PRO
Cantor Fitzgerald Downgrades Crinetics Pharmaceuticals to Neutral

Cantor Fitzgerald analyst Josh Schimmer downgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) from Overweight to Neutral.
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved